Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile

Fineline Cube Jul 2, 2026
Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026
Company Drug

Luye Pharma’s Paliperidone Palmitate Accepted for NMPA Review

Fineline Cube Dec 28, 2022

China-based Luye Pharma Group (HKG: 2186) has announced that the market filing for its paliperidone...

Policy / Regulatory

China Downgrades COVID-19 from Class A to Class B Infectious Disease

Fineline Cube Dec 28, 2022

The National Health Commission (NHC) has issued a notice downgrading COVID-19 from a Class A...

Company Deals

Carrier Biomed Raises ‘Tens of Millions’ in Series A+ Financing Round

Fineline Cube Dec 28, 2022

Carrier Biomed (Soohow) Co., Ltd, an exosome technology developer based in Suzhou, has reportedly raised...

Company

Everest Medicines Launches First Phase of Global mRNA Vaccine Manufacturing Site

Fineline Cube Dec 28, 2022

China-based Everest Medicines (HKG: 1952) has announced the initiation of the operation of the first...

Company Drug

InnoCare Pharma Receives Hong Kong Approval for Tafasitamab in DLBCL

Fineline Cube Dec 28, 2022

China-based biopharma InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the...

Company Deals

LeadArt Biotechnologies Raises USD 6 Million in Pre-Series A Round

Fineline Cube Dec 28, 2022

LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to...

Company Drug

Simcere Receives NMPA Clearance for SIM0237 Clinical Study

Fineline Cube Dec 28, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...

Company Drug

CStone Pharmaceuticals Publishes Ayvakit Study Results on Oncologist Website

Fineline Cube Dec 28, 2022

China-based CStone Pharmaceuticals (HKG: 2616) has published the results of the China-based bridging NAVIGATOR study...

Company Deals

Biosion Completes Series B Financing Round Led by Guangfa Xinde Investment

Fineline Cube Dec 28, 2022

Biosion, a global, clinical-stage biotech committed to developing antibody-based therapies targeting immune and oncologic diseases,...

Company Medical Device

BGI Genomics Receives ANVISA Approval for Colorectal Cancer Detection Kit

Fineline Cube Dec 28, 2022

China-based genomics giant BGI Genomics Co., Ltd (SHE: 300676) has reported receiving product approval from...

Company Deals

InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China

Fineline Cube Dec 28, 2022

Germany-based biopharma InflaRx N.V. (Nasdaq: IFRX) has revealed an amendment to its underlying deal with...

Company Drug

Elpiscience Receives IND Approval for ES014 in China

Fineline Cube Dec 27, 2022

Shanghai-based Elpiscience Biopharmaceuticals Inc. has announced receiving Investigational New Drug (IND) approval in China to...

Company Deals

Ablaze Pharma and Yonghe Partner for Targeted Radiotherapy Development

Fineline Cube Dec 27, 2022

China-based Ablaze Pharma and Yonghe Pharmaceutical have struck a partnership agreement for the research and...

Company Drug

InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA

Fineline Cube Dec 27, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...

Company Drug

Hainan Poly Pharm Receives FDA Approval for Generic Lincomycin

Fineline Cube Dec 27, 2022

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Company Drug

Innovent Biologics’ GFH925 Receives Breakthrough Therapy Designation

Fineline Cube Dec 27, 2022

China’s Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics (HKG: 1801) has...

Policy / Regulatory

Sichuan Healthcare Security Administration Announces VBP for Oral Implant Systems

Fineline Cube Dec 27, 2022

The Sichuan Provincial Healthcare Security Administration has released a notification regarding the inter-provincial alliance volume-based...

Company Drug

Junshi Biosciences’ PD-1 Inhibitor Tuoyi Faces FDA Review Delay

Fineline Cube Dec 27, 2022

Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that they have not received...

Company Drug

Huadong Medicine’s Lanluma V and X Approved for Use in Hainan

Fineline Cube Dec 27, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval from the Hainan Medical...

Company Drug

Antengene and MSD Collaborate on Global Clinical Study for ATG-037

Fineline Cube Dec 27, 2022

China-based Antengene Corporation Limited (HKG: 6996) has announced a global clinical collaboration with Merck, Sharp...

Posts pagination

1 … 605 606 607 … 689

Recent updates

  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
  • Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets
  • Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics
  • Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval
  • Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile

Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.